secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lucid Diagnostics Inc. (LUCD)
CIK:        0001799011
Form:       8-K
Filed at:   2024-05-02T23:59:59+00:00
Accession:  0001493152-24-017587
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lucid Diagnostics announces positive NCI study: EsoGuard detects 89% of short-segment precancers
--------------------------------------------------------------------------------

- EsoGuard showed 89% sensitivity for short-segment Barrett's esophagus (SSBE) in NCI-sponsored multicenter study.
- Detected 100% of cancers; overall sensitivity/specificity 85% each; estimated NPV 98% and PPV 39%.
- Study published in American Journal of Gastroenterology; investigators from Mayo Clinic, Johns Hopkins, Cleveland Clinic.
- Company plans to seek Medicare coverage via MolDX pre-submission meeting and formal technical assessment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1799011/000149315224017587/0001493152-24-017587-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1799011/000149315224017587/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-017587

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer